Beauty industry confronts weight-loss drug disruption

The boardrooms of the world's largest beauty companies are confronting an unexpected competitor: pharmaceutical weight-loss drugs. L'Oreal's leadership has publicly identified the widespread use of GLP-1 medications—injectable treatments originally developed for diabetes—as a material headwind for cosmetics and skin-care sales.

The drugs, which include Ozempic and Wegovy, suppress appetite and have become a cultural phenomenon among affluent consumers seeking rapid weight loss. As their adoption spreads, beauty firms report that consumers are spending less on makeup, skincare, and grooming products, a shift that translates into measurable revenue declines.

The phenomenon exposes how quickly consumer behaviour can shift when pharmaceutical options alter the calculus of appearance and health. For multinational beauty firms accustomed to decades of stable market dynamics, the disruption is forcing strategic recalibration.